Cipla Q1 FY27 Results Analysis: Margin Compresses 881 bps, PAT Plunges 39%

CompoundingAI Research Updated July 23, 2026 2 min read

Negative

Cipla Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 7,119.28 Cr (+2.33% YoY) and PAT growth of -39.19% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	July 23, 2026
Quarter	Q1 FY 2026-2027
Revenue (Q1)	Rs. 7,119.28 Cr (+2.33% YoY)
PAT (Q1)	Rs. 789.05 Cr (-39.19% YoY)
EBITDA margin	16.75% (-881 bps YoY)
EPS (Q1)	Rs. 9.77 (-39.20% YoY)
Market cap	Rs. 112,593.44 Cr
CMP	Rs. 1,393.75

Quarter Snapshot

Cipla's Q1 FY27 results show severe margin compression (EBITDA margin down 881 bps YoY to 16.75%) and a 39% PAT decline, driven by material cost inflation, employee cost growth, and US generics headwinds. Revenue grew only 2.33% YoY, with sequential improvement from Q4 trough providing limited comfort. The NPPA contingent liability of Rs.2,011 Cr remains a risk. Management's H2-weighted margin guidance of 18.5-20% requires meaningful US launch contributions to be achieved.

Key Investment Insights

Key Positives

Revenue recovered 8.84% QoQ from Q4 FY26 trough, driven by seasonal pattern and initial new launch contribution.
EBITDA margin improved sequentially from 15.24% to 16.75%, in line with H2-weighted guidance trajectory.
Standalone PAT grew 124.15% QoQ to Rs.862.16 Cr, recovering from the Q4 FY26 trough which included a Rs.31 Cr associate impairment.
No exceptional items were recorded in Q1 FY27, versus a Rs.275.91 Cr charge in FY26.
New subsidiaries incorporated (CiplaRna GmbH, Cipla Middle East, Aspergen) for future growth.

Risk Factors

EBITDA margin compressed 881 bps YoY to 16.75%, driven by material cost (+626 bps) and employee cost (+217 bps) inflation.
Consolidated PAT declined 39.19% YoY to Rs.789.05 Cr, with earnings lagging revenue growth.
Total material cost ratio surged to 37.46% of revenue from 31.20% a year ago, reflecting API cost inflation and Ventolin inventory build.
Employee benefits expense grew 14.11% YoY, absorbing 217 bps more of revenue, indicating structural cost pressure.
NPPA litigation contingent liability of Rs.2,011 Cr remains unresolved, with no provision made.
US generics business continues to face Revlimid erosion and Lanreotide supply disruption, dragging consolidated profitability.